Catalog No.: PC-28214Not For Human Use, Lab Use Only.
KF-0210 is a potent, selective and oral EP4 receptor antagonist with binding IC50 of 18.6 nM, shows >500-fold selectivity over other prostaglandin receptors, including EP1, EP2, EP3, IP, DP1, and FP.
KF-0210 is a potent, selective and oral EP4 receptor antagonist with binding IC50 of 18.6 nM, shows >500-fold selectivity over other prostaglandin receptors, including EP1, EP2, EP3, IP, DP1, and FP.
KF-0210 increases LPS-induced TNFα release (IC50=4.5 nM) in the presence of PGE2 in human PBMCs.
KF-0210 inhibits PGE2-induced cAMP production with IC50 of 1.06 nM in MCF-7 cells and 0.915 nM in Flpin-293-mEP4 cells.
KF-0210 increases the tumor-killing immune cells in the tumor in CT26 mouse model of colorectal cancer.
Combination treatment of KF-0210 and PD-1/PD-L1 antibodies shows a superior therapeutic effect compared to the monotherapy of each treatment.
